SGLT2 Inhibitors vs. GLP-1 Agonists to Treat the Heart, the Kidneys and the Brain.

Rolek, Bartosz; Haber, Mateusz; Gajewska, Magdalena; Rogula, Sylwester; Pietrasik, Arkadiusz; Gasecka, Aleksandra

Rolek, Bartosz; Haber, Mateusz; Gajewska, Magdalena; Rogula, Sylwester; Pietrasik, Arkadiusz; Gasecka, Aleksandra.

Afiliación

Rolek B; 1st Chair and Department of Cardiology, Medical University of Warsaw, 02-097 Warsaw, Poland.
Haber M; 1st Chair and Department of Cardiology, Medical University of Warsaw, 02-097 Warsaw, Poland.
Gajewska M; 1st Chair and Department of Cardiology, Medical University of Warsaw, 02-097 Warsaw, Poland.
Rogula S; 1st Chair and Department of Cardiology, Medical University of Warsaw, 02-097 Warsaw, Poland.
Pietrasik A; 1st Chair and Department of Cardiology, Medical University of Warsaw, 02-097 Warsaw, Poland.
Gasecka A; 1st Chair and Department of Cardiology, Medical University of Warsaw, 02-097 Warsaw, Poland.

J Cardiovasc Dev Dis ; 10(8)2023 Jul 30.

Article en En | MEDLINE | ID: mdl-37623335

Palabras clave

GLP-1-R agonists; SGLT2 inhibitors; cardiovascular outcomes; chronic kidney disease; combination therapy; heart failure

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Clinical_trials / Guideline / Risk_factors_studies Idioma: En Revista: J Cardiovasc Dev Dis Año: 2023 Tipo del documento: Article País de afiliación: Polonia Pais de publicación: Suiza

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google